{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T06:55:05Z","timestamp":1783234505156,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"AbbVie GK","award":["AbbVie GK"],"award-info":[{"award-number":["AbbVie GK"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10384-022-00923-2","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T05:02:55Z","timestamp":1654578175000},"page":"394-404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of systemic corticosteroids in patients newly \ufeffregistered at a claims database with a diagnosis of non-infectious uveitis: results from a real-world claims database analysis"],"prefix":"10.1007","volume":"66","author":[{"given":"Akihiko","family":"Umazume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Ohguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle A.","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Tsuruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"923_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/bjo.80.4.332","volume":"80","author":"A Rothova","year":"1996","unstructured":"Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332\u20136.","journal-title":"Br J Ophthalmol"},{"key":"923_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ophtha.2015.10.028","volume":"123","author":"AD Dick","year":"2016","unstructured":"Dick AD, Tundia N, Sorg R, Zhao C, Chao J, Joshi A, et al. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2016;123:655\u201362.","journal-title":"Ophthalmology"},{"key":"923_CR3","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.ophtha.2006.04.022","volume":"113","author":"A Iwase","year":"2006","unstructured":"Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y, Tajimi Study Group. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi study. Ophthalmology. 2006;113:1354\u201362.","journal-title":"Ophthalmology"},{"key":"923_CR4","doi-asserted-by":"publisher","first-page":"e14668","DOI":"10.1097\/MD.0000000000014668","volume":"98","author":"M Takeuchi","year":"2019","unstructured":"Takeuchi M, Kanda T, Kaburaki T, Tanaka R, Namba K, Kamoi K, et al. Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan: a multicenter study. Med (Baltim). 2019;98:e14668.","journal-title":"Med (Baltim)"},{"key":"923_CR5","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2147\/OPTH.S132184","volume":"11","author":"R Takahashi","year":"2017","unstructured":"Takahashi R, Yoshida A, Inoda S, Okubo A, Kawashima H. Uveitis incidence in Jichi Medical University Hospital, Japan, during 2011\u20132015. Clin Ophthalmol. 2017;11:1151\u20136.","journal-title":"Clin Ophthalmol"},{"key":"923_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/BF00185291","volume":"234","author":"S Kotake","year":"1996","unstructured":"Kotake S, Furudate N, Sasamoto Y, Yoshikawa K, Goda C, Matsuda H. Characteristics of endogenous uveitis in Hokkaido, Japan. Graefes Arch Clin Exp Ophthalmol. 1996;234:599\u2013603.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"923_CR7","first-page":"847","volume":"116","author":"S Hikita","year":"2012","unstructured":"Hikita S, Sonoda KH, Hijioka K, Fujimoto T, Ito T, Ishibashi T. Incidence of uveitis in the northern Kyushu region of Japan\u2013comparison between the periods of 1996\u20132001 and 2003\u20132008. Nippon Ganka Gakkai zasshi. 2012;116:847\u201355. [in Japanese].","journal-title":"Nippon Ganka Gakkai zasshi"},{"issue":"Sup 1","key":"923_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/09273948.2016.1184286","volume":"25","author":"D Iwata","year":"2017","unstructured":"Iwata D, Mizuuchi K, Aoki K, Horie Y, Kase S, Namba K, et al. Serial frequencies and clinical features of uveitis in Hokkaido, Japan. Ocul Immunol Inflamm. 2017;25(Sup 1):15\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"923_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/09273948.2014.920036","volume":"23","author":"H Nakahara","year":"2015","unstructured":"Nakahara H, Kaburaki T, Takamoto M, Okinaga K, Matsuda J, Konno Y, et al. Statistical analyses of endogenous uveitis patients (2007\u20132009) in central Tokyo area and comparison with previous studies (1963\u20132006). Ocul Immunol Inflamm. 2015;23:291\u20136.","journal-title":"Ocul Immunol Inflamm"},{"issue":"Sup 1","key":"923_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3109\/09273948.2015.1133840","volume":"25","author":"H Nakahara","year":"2017","unstructured":"Nakahara H, Kaburaki T, Tanaka R, Takamoto M, Ohtomo K, Karakawa A, et al. Frequency of uveitis in the central Tokyo area (2010\u20132012). Ocul Immunol Inflamm. 2017;25(Sup 1):8\u201314.","journal-title":"Ocul Immunol Inflamm"},{"key":"923_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12886-018-0871-6","volume":"18","author":"S Shirahama","year":"2018","unstructured":"Shirahama S, Kaburaki T, Nakahara H, Tanaka R, Takamoto M, Fujino Y, et al. Epidemiology of uveitis (2013\u20132015) and changes in the patterns of uveitis (2004\u20132015) in the central Tokyo area: a retrospective study. BMC Ophthalmol. 2018;18:189.","journal-title":"BMC Ophthalmol"},{"key":"923_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10384-012-0158-z","volume":"56","author":"N Ohguro","year":"2012","unstructured":"Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432\u20135.","journal-title":"Jpn J Ophthalmol"},{"key":"923_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10384-006-0383-4","volume":"51","author":"H Goto","year":"2007","unstructured":"Goto H, Mochizuki M, Yamaki K, Kotake S, Usui M, Ohno S. Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007;51:41\u20134.","journal-title":"Jpn J Ophthalmol"},{"key":"923_CR14","first-page":"635","volume":"123","author":"Japanese Ocular Inflammation Society","year":"2019","unstructured":"Japanese Ocular Inflammation Society. Guideline for treatment of uveitis (June 10, 2019). Nippon Ganka Gakkai zasshi. 2019;123:635\u201396. [in Japanese].","journal-title":"Nippon Ganka Gakkai zasshi"},{"key":"923_CR15","first-page":"225","volume":"77","author":"S Mishima","year":"1979","unstructured":"Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K. The eighth Frederick H. Verhoeff lecture. Beh\u00e7et\u2019s disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc. 1979;77:225\u201379.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"923_CR16","first-page":"394","volume":"116","author":"Committee for the Preparation of Clinical Treatment of Ocular Lesions Related to Beh\u00e7et\u2019s Disease","year":"2012","unstructured":"Committee for the Preparation of Clinical Treatment of Ocular Lesions Related to Beh\u00e7et\u2019s Disease. Guidelines for the clinical management of ocular Beh\u00e7et\u2019s disease. Nippon Ganka Gakkai zasshi. 2012;116:394\u2013426. [in Japanese].","journal-title":"Nippon Ganka Gakkai zasshi"},{"key":"923_CR17","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Beh\u00e7et\u2019s disease. N Engl J Med. 1999;341:1284\u201391.","journal-title":"N Engl J Med"},{"key":"923_CR18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s10792-016-0395-0","volume":"37","author":"CP Herbort Jr","year":"2017","unstructured":"Herbort CP Jr, Abu El Asrar AM, Yamamoto AM, Pav\u00e9sio JH, Gupta CE, Khairallah VM, et al. Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality. Int Ophthalmol. 2017;37:1383\u201395.","journal-title":"Int Ophthalmol"},{"key":"923_CR19","unstructured":"Japan Society of Sarcoidosis and other Granulomatous Disorders. Guidance on sarcoidosis treatment. 2018. https:\/\/www.jssog.com\/journal. Accessed 1 February 2022. [in Japanese]."},{"key":"923_CR20","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39:2216\u201329.","journal-title":"Clin Ther"},{"key":"923_CR21","volume-title":"Corticosteroid adverse effects","author":"M Yasir","year":"2021","unstructured":"Yasir M, Goyal A, Bansal P, Sonthalia S. Corticosteroid adverse effects. Treasure Island (FL): StatPearls Publishing LLC; 2021."},{"key":"923_CR22","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JWJ, de Wit M, Boers M, Caeyers N, Cutolo M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75:952\u20137.","journal-title":"Ann Rheum Dis"},{"key":"923_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1080\/09273948.2018.1559928","volume":"28","author":"H Nakahara","year":"2020","unstructured":"Nakahara H, Kaburaki T, Tanaka R, Yoshida A, Takamoto M, Kawata M, et al. Comparisons of clinical features in Japanese patients with Beh\u00e7et\u2019s uveitis treated in the 1990s and the 2000s. Ocul Immunol Inflamm. 2020;28:262\u20139.","journal-title":"Ocul Immunol Inflamm"},{"key":"923_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10384-021-00850-8","volume":"65","author":"A Umazume","year":"2021","unstructured":"Umazume A, Ohguro N, Okada AA, Namba K, Sonoda K, Tsuruga H, et al. Prevalence and incidence rates and treatment patterns of non-infectious uveitis in Japan: real-world data using a claims database. Jpn J Ophthalmol. 2021;65:657\u201365.","journal-title":"Jpn J Ophthalmol"},{"key":"923_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2188\/jea.JE20090066","volume":"20","author":"S Kimura","year":"2010","unstructured":"Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20:413\u20139.","journal-title":"J Epidemiol"},{"key":"923_CR26","unstructured":"Statistics Bureau, Ministry of Internal Affairs and Communications. Result of the Population Estimates. https:\/\/www.stat.go.jp\/english\/data\/jinsui\/2.html. Accessed 1 February 2022."},{"key":"923_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2016.05.002","volume":"62","author":"GAD O\u2019Keefe","year":"2017","unstructured":"O\u2019Keefe GAD, Rao NA. Vogt-Koyanagi-Harada disease. Surv Ophthalmol. 2017;62:1\u201325.","journal-title":"Surv Ophthalmol"},{"key":"923_CR28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1530\/eje.0.1510397","volume":"151","author":"C Grossmann","year":"2004","unstructured":"Grossmann C, Scholz T, Rochel M, Bumke-Vogt C, Oelkers W, Pfeiffer AFH, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004;151:397\u2013406.","journal-title":"Eur J Endocrinol"},{"key":"923_CR29","unstructured":"Medical Care Act. Law number: Act No. 205 of 1948. https:\/\/www.mhlw.go.jp\/web\/t_doc?dataId=80090000&dataType=0&pageNo=1. Accessed 1 February 2022. [in Japanese]."},{"key":"923_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10384-020-00809-1","volume":"65","author":"KH Sonoda","year":"2021","unstructured":"Sonoda KH, Hasegawa E, Namba K, Okada AA, Ohguro N, Goto H. JOIS (Japanese Ocular Inflammation Society) Uveitis Survey Working Group. Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol. 2021;65:184\u201390.","journal-title":"Jpn J Ophthalmol"},{"key":"923_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10792-009-9336-5","volume":"30","author":"JI Sakai","year":"2010","unstructured":"Sakai JI, Usui Y, Sakai M, Yokoi H, Goto H. Clinical statistics of endogenous uveitis: comparison between general eye clinic and university hospital. Int Ophthalmol. 2010;30:297\u2013301.","journal-title":"Int Ophthalmol"},{"key":"923_CR32","first-page":"157803","volume":"2014","author":"Y Wang","year":"2014","unstructured":"Wang Y, Chan CC. Gender differences in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. J Ophthalmol. 2014;2014:157803.","journal-title":"J Ophthalmol"},{"key":"923_CR33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/ard.2006.064543","volume":"66","author":"B Vander Cruyssen","year":"2007","unstructured":"Vander Cruyssen B, Ribbens C, Boonen A, Mielants H, de Vlam K, Lenaerts J, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis. 2007;66:1072\u20137.","journal-title":"Ann Rheum Dis"},{"key":"923_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaapos.2008.03.007","volume":"12","author":"K Sabri","year":"2008","unstructured":"Sabri K, Saurenmann RK, Silverman ED, Levin AV. Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS. 2008;12:539\u201345.","journal-title":"J AAPOS"},{"key":"923_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/clpt.1988.43","volume":"43","author":"AE Stuck","year":"1988","unstructured":"Stuck AE, Frey BM, Frey FJ. Kinetics of prednisolone and endogenous cortisol suppression in the elderly. Clin Pharmacol Ther. 1988;43:354\u201362.","journal-title":"Clin Pharmacol Ther"},{"key":"923_CR36","unstructured":"Shionogi & Co., Ltd. Predonine\u00ae 5\u00a0mg tablets Japanese package insert, version 1 (revised. July 2020). https:\/\/www.info.pmda.go.jp\/go\/pack\/2456001F1310_4_02\/. Accessed 1 February 2022. [in Japanese]."},{"key":"923_CR37","doi-asserted-by":"publisher","first-page":"e025806","DOI":"10.1136\/bmjopen-2018-025806","volume":"9","author":"R Nishimura","year":"2019","unstructured":"Nishimura R, Kato H, Kisanuki K, Oh A, Hiroi S, Onishi Y, et al. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. BMJ Open. 2019;9:e025806.","journal-title":"BMJ Open"},{"key":"923_CR38","first-page":"697","volume":"123","author":"Japanese Ophthalmological Society","year":"2019","unstructured":"Japanese Ophthalmological Society. Guidance and safety manual on the use of anti-TNF agents in non-infectious uveitis (revised version 2). Nippon Ganka Gakkai zasshi. 2019;123:697\u2013705. [in Japanese].","journal-title":"Nippon Ganka Gakkai zasshi"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00923-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-022-00923-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00923-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T03:30:02Z","timestamp":1655523002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-022-00923-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1007\/s10384-022-00923-2","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"20 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A. Umazume, None; N. Ohguro, None; A. A. Okada, Grants (Bayer, Novartis, Santen, Mitsubishi Tanabe, Alcon, Kowa), Consulting fees (Bayer, AbbVie, Astellas, Biocon Biologics, Daiichi Sankyo, Allergan, Chugai, Novartis), Speaker fees (Bayer, Kowa, Novartis, Santen, Mitsubishi Tanabe, Senju, Alcon, Otsuka, Allergan); K. Namba, Grant (AbbVie, Mitsubishi Tanabe, Eisai, EP-CRSU), Speaker fees (Alcon, Pfizer, Novartis, Kowa, Senju, Mitsubishi Tanabe, Eisai, AbbVie, Santen, Celgene); K. Sonoda, None; H. Goto, None; H. Tsuruga and K. Morita are employees of AbbVie GK and may receive stocks\ufeff.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}